High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2014-10, Vol.86 (1), p.113-114
Hauptverfasser:	Fujita, Ken-ichi, Hirose, Takashi, Kusumoto, Sojiro, Sugiyama, Tomohide, Shirai, Takao, Nakashima, Masanao, Akiyama, Yuko, Sasaki, Yasutsuna
Format:	Artikel
Sprache:	eng
Schlagworte:	ABCG2 Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Erlotinib Erlotinib Hydrochloride Hematology, Oncology and Palliative Medicine High exposure Humans Interstitial lung disease Lung Diseases, Interstitial - chemically induced Lung Neoplasms - complications Lung Neoplasms - drug therapy Pharmacokinetics Polymorphism Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Quinazolines - adverse effects Quinazolines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!